| Predicted Trait | |
| Reported Trait | Systolic blood pressure |
| Mapped Trait(s) | systolic blood pressure (EFO_0006335) |
| Score Construction | |
| PGS Name | SBP-meta-analysis |
| Development Method | |
| Name | SBayesRC |
| Parameters | Meta-GWAS results were filtered on per-SNP sample size (N) in the range mean_N +- 4 * SD_N |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 7,356,519 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000581 |
| Citation (link to publication) | Keaton JM et al. Nat Genet (2024) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 1,028,980 individuals (100%) |
| PGS Evaluation | African: 50% European: 50% 2 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
| — | 1,028,980 individuals | European | BioVU, ICBP, MVP, UKB |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM020761 | PSS011397| European Ancestry| 10,210 individuals |
PGP000581 | Keaton JM et al. Nat Genet (2024) |
Reported Trait: Systolic blood pressure | — | — | R²: 0.1137 beta (high vs low tertile): 16.85 |
Age, Age2, Sex, BMI | — |
| PPM020764 | PSS011396| African Ancestry| 21,843 individuals |
PGP000581 | Keaton JM et al. Nat Genet (2024) |
Reported Trait: Systolic blood pressure | — | — | beta (high vs low tertile): 10.59 | Age, Age2, Sex, BMI | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011396 | the earliest median eligible non-Emergency Department outpatient measured SBP in the electronic health record, and the corresponding DBP. For individuals with an even number of SBP measures in their record, the lower value was used to compute the median. For individuals with fewer than three measurements available, the lowest available SBP and corresponding DBP were used. Measures were considered ineligible if they occurred at or after an ICD-9/10 billing code from the groups 585/N18 (chronic kidney disease), 405/I15 (secondary hypertension), or 428/I50 (heart failure). For participants who had started an antihypertensive medication before the date of their median SBP measurement, 15 mm Hg was added to SBP and 10 mm Hg to DBP. Eligible SBP measures were restricted to a range of 30 to 300 mmHg. Eligible DBP measures were restricted to values over 30 mmHg. Eligible DBP measures were restricted to values over 30 mmHg. Sample size for SBP, DBP, and PP GWAS analysis included 21,843 individuals. Pulse pressure was defined as SBP minus DBP. Hypertension status was defined by phecodes 401* and/or antihypertensive medication use. | — | 21,843 individuals, 42.69 % Male samples |
Mean = 48.3 years Sd = 14.75 years |
African American or Afro-Caribbean (American) |
— | AllofUs | — |
| PSS011397 | In Lifelines, BP was measured every minute during a period of ten minutes using an automated DINAMAP Monitor (GE Healthcare) and the average of the final three readings was recorded for SBP and DBP. Participants with a measured BP ≥140/90 mm Hg irrespective of treatment and those taking antihypertensive medication (ATC codes C02, C03, C07, C08, C09) irrespective of BP were defined as having hypertension. In continuous trait analyses, 15 mm Hg was added to SBP and 10 mm Hg was added to DBP for 1,236 individuals who were taking antihypertensive medication. PP was calculated using these medication-adjusted BP values. | — | 10,210 individuals, 41.6 % Male samples |
Mean = 44.66 years Sd = 13.05 years |
European (Dutch) |
— | LifeLines | — |